Ethnic Differences in 90-Day Poststroke Medication Adherence. 2019

Rebecca J Lank, and Lynda D Lisabeth, and Deborah A Levine, and Darin B Zahuranec, and Kevin A Kerber, and Fatema Shafie-Khorassani, and Erin Case, and Belinda G Zuniga, and George M Cooper, and Devin L Brown, and Lewis B Morgenstern
From the Stroke Program (R.J.L., L.D.L., D.A.L., D.B.Z., K.A.K., B.G.Z., G.M.C., D.L.B., L.B.M.), University of Michigan, Ann Arbor.

Background and Purpose- We assessed ethnic differences in medication adherence 3 months poststroke in a population-based study as an initial step in investigating the increased stroke recurrence risk in Mexican Americans compared with non-Hispanic whites. Methods- Ischemic stroke cases from 2008 to 2015 from the Brain Attack Surveillance in Corpus Christi project in Texas were followed prospectively for 3 months poststroke to assess medication adherence. Medications in 5 drug classes were analyzed: statins, antiplatelets, anticoagulants, antihypertensives, and antidepressants. For each drug class, patients were considered adherent if they reported never missing a dose in a typical week. The χ2 tests or Kruskal-Wallis nonparametric tests were used for ethnic comparisons of demographics, risk factors, and medication adherence. A multivariable logistic regression model was constructed for the association of ethnicity and medication nonadherence. Results- Mexican Americans (n=692) were younger (median 65 years versus 68 years, P<0.001), had more diabetes mellitus ( P<0.001) and hypertension ( P<0.001) and less atrial fibrillation ( P=0.003), smoking ( P=0.003), and education ( P<0.001) than non-Hispanic whites (n=422). Sex, insurance status, high cholesterol, previous stroke/transient ischemic attack history, excessive alcohol use, tPA (tissue-type plasminogen activator) treatment, National Institutes of Health Stroke Scale score, and comorbidity index did not significantly differ by ethnicity. There was no significant difference in medication adherence for any of the 5 drug classes between Mexican Americans and non-Hispanic whites. Conclusions- This study did not find ethnic differences in medication adherence, thus challenging this patient-level factor as an explanation for stroke recurrence disparities. Other reasons for the excessive stroke recurrence burden in Mexican Americans, including provider and health system factors, should be explored.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013781 Texas State bounded on the north by Oklahoma, on the east by Arkansas and Louisiana, on the south by Mexico, and on the west by New Mexico.
D017058 Mexican Americans Persons living in the United States of Mexican descent. Chicanos,Chicanas,American, Mexican,Americans, Mexican,Chicana,Chicano,Mexican American
D044465 White People Persons having origins in any of the white racial groups of Europe, the Middle East, or North Africa. Note that OMB category WHITE is available for the United States population groups. Race and ethnicity terms, as used in the federal government, are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. European Continental Ancestry Group,White Person,Caucasian Race,Caucasoid Race,Caucasian Races,Caucasoid Races,People, White,Person, White,Race, Caucasian,Race, Caucasoid,White Peoples,White Persons
D055118 Medication Adherence Voluntary cooperation of the patient in taking drugs or medicine as prescribed. This includes timing, dosage, and frequency. Drug Adherence,Drug Compliance,Medication Compliance,Medication Nonadherence,Medication Non-Adherence,Medication Non-Compliance,Medication Noncompliance,Medication Persistence,Adherence, Drug,Adherence, Medication,Compliance, Drug,Compliance, Medication,Medication Non Adherence,Medication Non Compliance,Non-Adherence, Medication,Non-Compliance, Medication,Nonadherence, Medication,Noncompliance, Medication,Persistence, Medication

Related Publications

Rebecca J Lank, and Lynda D Lisabeth, and Deborah A Levine, and Darin B Zahuranec, and Kevin A Kerber, and Fatema Shafie-Khorassani, and Erin Case, and Belinda G Zuniga, and George M Cooper, and Devin L Brown, and Lewis B Morgenstern
September 2019, Stroke,
Rebecca J Lank, and Lynda D Lisabeth, and Deborah A Levine, and Darin B Zahuranec, and Kevin A Kerber, and Fatema Shafie-Khorassani, and Erin Case, and Belinda G Zuniga, and George M Cooper, and Devin L Brown, and Lewis B Morgenstern
November 2011, The American journal of managed care,
Rebecca J Lank, and Lynda D Lisabeth, and Deborah A Levine, and Darin B Zahuranec, and Kevin A Kerber, and Fatema Shafie-Khorassani, and Erin Case, and Belinda G Zuniga, and George M Cooper, and Devin L Brown, and Lewis B Morgenstern
January 2014, Stroke research and treatment,
Rebecca J Lank, and Lynda D Lisabeth, and Deborah A Levine, and Darin B Zahuranec, and Kevin A Kerber, and Fatema Shafie-Khorassani, and Erin Case, and Belinda G Zuniga, and George M Cooper, and Devin L Brown, and Lewis B Morgenstern
January 2021, Journal of the American Heart Association,
Rebecca J Lank, and Lynda D Lisabeth, and Deborah A Levine, and Darin B Zahuranec, and Kevin A Kerber, and Fatema Shafie-Khorassani, and Erin Case, and Belinda G Zuniga, and George M Cooper, and Devin L Brown, and Lewis B Morgenstern
February 2011, The Annals of pharmacotherapy,
Rebecca J Lank, and Lynda D Lisabeth, and Deborah A Levine, and Darin B Zahuranec, and Kevin A Kerber, and Fatema Shafie-Khorassani, and Erin Case, and Belinda G Zuniga, and George M Cooper, and Devin L Brown, and Lewis B Morgenstern
April 2009, Expert review of cardiovascular therapy,
Rebecca J Lank, and Lynda D Lisabeth, and Deborah A Levine, and Darin B Zahuranec, and Kevin A Kerber, and Fatema Shafie-Khorassani, and Erin Case, and Belinda G Zuniga, and George M Cooper, and Devin L Brown, and Lewis B Morgenstern
October 2017, European journal of clinical investigation,
Rebecca J Lank, and Lynda D Lisabeth, and Deborah A Levine, and Darin B Zahuranec, and Kevin A Kerber, and Fatema Shafie-Khorassani, and Erin Case, and Belinda G Zuniga, and George M Cooper, and Devin L Brown, and Lewis B Morgenstern
February 2004, The Annals of pharmacotherapy,
Rebecca J Lank, and Lynda D Lisabeth, and Deborah A Levine, and Darin B Zahuranec, and Kevin A Kerber, and Fatema Shafie-Khorassani, and Erin Case, and Belinda G Zuniga, and George M Cooper, and Devin L Brown, and Lewis B Morgenstern
May 2008, Diabetes care,
Rebecca J Lank, and Lynda D Lisabeth, and Deborah A Levine, and Darin B Zahuranec, and Kevin A Kerber, and Fatema Shafie-Khorassani, and Erin Case, and Belinda G Zuniga, and George M Cooper, and Devin L Brown, and Lewis B Morgenstern
September 2021, Exploratory research in clinical and social pharmacy,
Copied contents to your clipboard!